MediFind

Find a Doctor

Bertrand B. Coiffier

Centre Hospitalier Lyon Sud
Male

Bio


Bertrand Coiffier is in Pierre-la-treiche, France. They have been an author on 239 peer reviewed articles in the past 15 years. Dr. Coiffier's top three areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma.

Contact

Pierre-la-treiche, FR

Latest Research


Latest Advance
Study
  • Condition: Patients with Diffuse Large B-Cell Lymphoma Responding to R-CHOP
  • Journal: British journal of haematology
  • Treatment Used: Lenalidomide Maintenance
  • Number of Patients: 457
  • Published —
This study analyzed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL) in patients with diffuse large B-cell lymphoma (DLBCL).
Latest Advance
Study
  • Condition: Relapsed Chronic Lymphocytic Leukemia
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Rituximab with or without Idelalisib
  • Number of Patients: 220
  • Published —
This study compared the clinical outcome of using rituximab with or without idelalisib to treat patients with relapsed chronic lymphocytic leukemia.
Latest Advance
Study
  • Condition: Previously Untreated Low-tumor-burden Follicular Lymphoma
  • Journal: The Lancet. Haematology
  • Treatment Used: CT-P10 versus rituximab
  • Number of Patients: 258
  • Published —
The purpose of the study was to assess the therapeutic value of single-agent CT-P10 versus rituximab in patients with newly diagnosed low-tumor burden follicular lymphoma.

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Study
  • Journal: International journal of environmental research and public health
  • Published —
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Contact

Pierre-la-treiche, FR

Insurance

Contact them to find out if they accept your insurance plan.